AB Therapeutics

Ability Pharmaceuticals (legally AB Therapeutics, S.L.) is a clinical-stage biopharmaceutical company based in Barcelona, Spain, focused on developing first-in-class autophagy-inducing small molecules for oncology. The company's lead candidate, ABTL0812, is a targeted oral therapy that induces cancer cell death by inhibiting the Akt/mTORC1 pathway and triggering endoplasmic reticulum stress via PPAR-alpha/gamma activation. ABTL0812 has demonstrated efficacy and a favorable safety profile in Phase 2 clinical trials for endometrial and non-small cell lung cancer, and is currently being evaluated in a Phase 2b trial for pancreatic cancer. AbilityPharma leverages its proprietary Membrane Lipid Therapy (MLT) platform to identify compounds that modulate cell signaling through membrane-protein interactions. The company has secured significant funding from European venture capital firms and the EIC Fund, and has established a major licensing agreement with SciClone Pharmaceuticals for the Greater China market.